−1.83USD
−210.96 MUSD
60.45 M
About Immunovant, Inc.
Sector
Industry
CEO
Peter Salzmann
Website
Headquarters
New York
Employees (FY)
164
Founded
2018
ISIN
US45258J1025
FIGI
BBG00P5MC0Q8
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of IMVT is 28.22 USD — it has decreased by 0.35% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Immunovant, Inc. stocks are traded under the ticker IMVT.
Immunovant, Inc. is going to release the next earnings report on May 20, 2024. Keep track of upcoming events with our Earnings Calendar.
IMVT stock is 4.80% volatile and has beta coefficient of 0.62. Check out the list of the most volatile stocks — is Immunovant, Inc. there?
One year price forecast for Immunovant, Inc. has a max estimate of 57.00 USD and a min estimate of 40.00 USD.
IMVT earnings for the last quarter are −0.45 USD per share, whereas the estimation was −0.45 USD resulting in a 0.75% surprise. The estimated earnings for the next quarter are −0.43 USD per share. See more details about Immunovant, Inc. earnings.
Yes, you can track Immunovant, Inc. financials in yearly and quarterly reports right on TradingView.
IMVT stock has fallen by 7.48% compared to the previous week, the month change is a 8.50% fall, over the last year Immunovant, Inc. has showed a 81.13% increase.
IMVT net income for the last quarter is −51.42 M USD, while the quarter before that showed −58.66 M USD of net income which accounts for 12.35% change. Track more Immunovant, Inc. financial stats to get the full picture.
Today Immunovant, Inc. has the market capitalization of 4.11 B, it has decreased by 0.84% over the last week.
No, IMVT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IMVT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Immunovant, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 164.00 employees. See our rating of the largest employees — is Immunovant, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Immunovant, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Immunovant, Inc. stock shows the buy signal. See more of Immunovant, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Immunovant, Inc. future price: according to them, IMVT price has a max estimate of 57.00 USD and a min estimate of 40.00 USD. Read a more detailed Immunovant, Inc. forecast: see what analysts think of Immunovant, Inc. and suggest that you do with its stocks.